By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
NASA's Artemis 2 pilot Victor Glover listens to 'Whitey on the Moon' every Monday. This is why. - 2Woman charged in unprovoked stabbing of tourist changing baby's diaper in Macy’s Herald Square store
- 3NASA's Artemis 2 moon launch may be visible from Florida and southern Georgia today. Here's when to look
- 4Finding the Universe of Computer generated Reality: Individual Encounters
- 5How Skoda Lost Its Biggest Market In Just Seven Years
- Germany unveils rescue plan for struggling chemical sector
- Doctors looking into hormone therapy as a way to ward off dementia in women
- 5 Signs Now is the ideal time to Update Your Android Telephone: When to Take the Action
- NASA’s history-making moon mission aims to send the first woman and person of color to deep space
- EU delays signing of Mercosur free trade deal
- Email Promoting Instruments for Compelling Efforts
- Iran plans new restrictions in overhaul of Strait of Hormuz rules
- Report: Russian military pressuring students to work as drone pilots
- Wisconsin judge sends Slender Man attacker back to mental health institution after group home escape
